Moxifloxacin in the treatment of skin and skin structure infections

References

• AckermannGSchaumannRPlessBComparative activity of moxifloxacin in vitro against obligately anerobic bacteriaEur J Clin Microbiol Infect Dis2000192283210795599
   PubMed Web of Science ®Google Scholar
• AlcaideFCalatayudLSantinMComparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasiiAntimicrob Agents Chemother2004484562515561826
   PubMed Web of Science ®Google Scholar
• AldridgeKEAshcraftDSComparison of the in vitro activities of Bay 12–8039, a new quinolone, and other antimicrobials against clinically important anaerobesAntimicrob Agents Chemother199741709119056020
   PubMed Web of Science ®Google Scholar
• Amabile-CuevasCFHermida-EscobedoCVivarRComparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenesClin Infect Dis200132Suppl 1S30211249826
   PubMedGoogle Scholar
• AndrioleVTHaverstockDCChoudhriSHRetrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trialsDrug Safety2005284435215853445
   PubMed Web of Science ®Google Scholar
• AnonymousAvelox® (moxifloxacin) product information2005West Haven, CTBayer HealthCare June 2005
   Google Scholar
• AubryAJarlierVEscolanoSAntibiotic susceptibility pattern of Mycobacterium marinumAntimicrob Agents Chemother2000443133611036036
   PubMed Web of Science ®Google Scholar
• BallPStahlmannRKubinRSafety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studiesClin Ther2004269405015336463
   PubMed Web of Science ®Google Scholar
• BallowCLettieriJAgarwalVAbsolute bioavailability of moxifloxacinClin Ther1999215132210321420
   PubMed Web of Science ®Google Scholar
• BarryALFuchsPCBrownSDAntibacterial activity of moxifloxacin (Bay 12–8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility testsEur J Clin Microbiol Infect Dis199918305910385024
   PubMed Web of Science ®Google Scholar
• BauernfeindAComparison of the antibacterial activities of the quinolones Bay 12–8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacinJ Antimicrob Chemother199740639519421311
   PubMed Web of Science ®Google Scholar
• BetriuCGomezMPalauMLActivities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agentsAntimicrob Agents Chemother1999432320210471590
   PubMed Web of Science ®Google Scholar
• BetriuCRodriguez-AvialIGomezMChanging patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997–2002)Diagn Microbiol Infect Dis200553221316243476
   PubMed Web of Science ®Google Scholar
• BiedenbachDJTolemanMAWalshTRCharacterization of fluoroquinolone-resistant β-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobiol Surveillance Program (1997–2004)Diagn Microbiol Infect Dis2006551192716530373
   PubMed Web of Science ®Google Scholar
• BlondeauJMLaskowskiRBjarnasonJComparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 gram-negative and gram-positive organismsInt J Antimicrob Agents200014455010717500
   PubMed Web of Science ®Google Scholar
• BlondeauJMThe role of fluoroquinolones in skin and skin structure infectionsAm J Clin Dermatol20023374611817967
   PubMedGoogle Scholar
• BogdanovichTEselDKellyLMAntistaphylococcal activity of DX-169, a new des-F(6)-quinolone, compared with those of other agentsAntimicrob Agents Chemother20054933253316048943
   PubMed Web of Science ®Google Scholar
• BoswellFJAndrewsJMWiseRPharmacodynamic properties of Bay 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effectAntimicrob Agents Chemother199741137799174203
   PubMed Web of Science ®Google Scholar
• BowkerKENoelARMacGowanAPIn vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogensInt J Antimicrob Agents2003225576114659651
   PubMed Web of Science ®Google Scholar
• BrabackMRiesbeckKForsgrenASusceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared with its susceptibilities to reference macrolides and quinolonesAntimicrob Agents Chemother20024611141611897601
   PubMed Web of Science ®Google Scholar
• BurkhardtOBornerKStassHSingle- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faecesScand J Infect Dis20023489890312587622
   PubMed Web of Science ®Google Scholar
• BurkhardtOStassHThussUEffects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteersClin Pharmacokinet2005449697616122283
   PubMed Web of Science ®Google Scholar
• ChenXCassJDBradleyJAQT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcomeBr J Pharmacol2005146792916158069
   PubMed Web of Science ®Google Scholar
• CreditoKLJacobsMRAppelbaumPCTime-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agentsAntimicrob Agents Chemother200347139940212654677
   PubMed Web of Science ®Google Scholar
• CritchleyIASahmDFThornsberryCAntimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999Diagn Microbiol Infect Dis2002421293511858909
   PubMed Web of Science ®Google Scholar
• DalhoffAPetersenUEndermannRIn vitro activity of Bay 12-8039, a new 8-methoxyquinoloneChemotherapy199642410258957575
   PubMed Web of Science ®Google Scholar
• DalhoffASchubertSUllmannUEffect of pH on the in vitro activity of and propensity for the emergence of resistance to fluoroquinolones, macrolides, and a ketolideInfection200533suppl 2364316518710
   PubMedGoogle Scholar
• DanMKeynanOFeldbrinZConcentrations of moxifloxacin in serum and synovial fluid, and ex vivo bactericidal activity against arthritis-causing pathogensDiagn Microbiol Infect Dis200448283615062922
   PubMed Web of Science ®Google Scholar
• DraenertRKunzelmannMRoggenkampAInfected cat-bite wound treated successfully with moxifloxacin after failure of parenteral cefuroxime and ciprofloxacinEur J Clin Microbiol Infect Dis2005242889015902538
   PubMed Web of Science ®Google Scholar
• DuncanKBarryCE3rdProspects for new antitubercular drugsCurr Opin Microbiol20047460515451500
   PubMed Web of Science ®Google Scholar
• EdlundCSabouriSNordCEComparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteriaEur J Clin Microbiol Infect Dis19981719359665302
   PubMed Web of Science ®Google Scholar
• EdmistonCEKrepelCJSeabrookGRIn vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infectionsAntimicrob Agents Chemother20044810121614982797
   PubMed Web of Science ®Google Scholar
• EdmistonCEKrepelCJKehlKSComparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic, and otolaryngologic surgical patientsJ Antimicrob Chemother200556872816186167
   PubMed Web of Science ®Google Scholar
• EdnieLMRattanAJacobsMRAntianaerobe activity of RBX 7644 (ranbezolid), a new oxazolidinone, compared with those of eight other agentsAntimicrob Agents Chemother2003471143712604558
   PubMed Web of Science ®Google Scholar
• ElbeDHChangSWMoxifloxacin-warfarin interaction: a series of five case reportsAnn Pharmacother200539361415632222
   PubMed Web of Science ®Google Scholar
• EspositoSNovielloSIannielloFBactericidal activity of moxifloxacin compared with grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic modelJ Chemother2000124758111154028
   PubMed Web of Science ®Google Scholar
• FassRJIn vitro activity of Bay 12–8039, a new 8-methoxyquinoloneAntimicrob Agents Chemother1997411818249257770
   PubMed Web of Science ®Google Scholar
• FuhrmannVSchenkPJaegerWPharmacokinetics of moxifloxacin in patients undergoing continuous venovenous hemodiafiltrationJ Antimicrob Chemother200454780415347636
   PubMed Web of Science ®Google Scholar
• Fung-TomcJCMinassianBKolekBAntibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756Antimicrob Agents Chemother2000443351611083639
   PubMed Web of Science ®Google Scholar
• GavinJR3rdKubinRChoudhriSMoxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studiesDrug Safety2004276718615230648
   PubMed Web of Science ®Google Scholar
• GillespieSHBillingtonOActivity of moxifloxacin against mycobacteriaJ Antimicrob Chemother199944393510511409
   PubMed Web of Science ®Google Scholar
• GiordanoPSongJPentelPSequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infectionInt J Antimicrob Agents2005263576516229991
   PubMed Web of Science ®Google Scholar
• GolanYMcDermottLAJacobusNVEmergence of fluoroquinolone resistance among Bacteroides speciesJ Antimicrob Chemother2003522081312865399
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMHudspethMIn vitro activity of Bay 12–8039, a new 8-methoxyquinolone, compared with the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humansAntimicrob Agents Chemother199741155279210683
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMMerriamCVComparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogensAntimicrob Agents Chemother20004427475110991855
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMMerriamCVIn vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella speciesAntimicrob Agents Chemother20024630687012183274
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMWarrenYAIn vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infectionsAntimicrob Agents Chemother2006501485516377680
   PubMed Web of Science ®Google Scholar
• GuayDRPPiscitelliSCRodvoldKAChapter 8. QuinolonesInfectious disease: drug interactions in infectious diseases20052nd edTotowa, NJHumana Pr.21554
   Google Scholar
• HardyDAmsterdamDMandellLAComparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocciAntimicrob Agents Chemother200044802510681365
   PubMed Web of Science ®Google Scholar
• HedbergMNordCEESCMID Study Group on Antimicrobial Resistance in Anaerobic BacteriaAntimicrobial susceptibility of Bacteroides fragilis group isolates in EuropeClin Microbiol Infect200394758812848722
   PubMed Web of Science ®Google Scholar
• HermsenEDHovdeLBSprandelKALevofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic modelAntimicrob Agents Chemother200549685915673752
   PubMed Web of Science ®Google Scholar
• HoellmanDBKellyLMJacobsMRComparative antianaerobic activity of BMS 284756Antimicrob Agents Chemother2001455899211158759
   PubMed Web of Science ®Google Scholar
• Hoogkamp-KorstanjeJARoelofs-WillemseJComparative in vitro activity of moxifloxacin against gram-positive clinical isolatesJ Antimicrob Chemother20004531910629010
   PubMed Web of Science ®Google Scholar
• HsuehPRTengLJLeeCMTelithromycin and quinupristin-dalfopristin resistance in clinical isolates of Streptococcus pyogenes: SMART Program 2001 DataAntimicrob Agents Chemother2003472152712821461
   PubMed Web of Science ®Google Scholar
• InceDZhangXHooperDCActivity of and resistance to moxifloxacin in Staphylococcus aureusAntimicrob Agents Chemother20034714101512654680
   PubMed Web of Science ®Google Scholar
• JacobsMRBajaksouzianSWindauAIn vitro activity of the new quinolone WCK 771 against staphylococciAntimicrob Agents Chemother20044833384215328094
   PubMed Web of Science ®Google Scholar
• JiBGrossetJCombination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosyLeprosy Rev200071SupplS81711201894
   PubMedGoogle Scholar
• JoukhadarCStassHMuller-ZellenbergUPenetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humansAntimicrob Agents Chemother200347309910314506015
   PubMed Web of Science ®Google Scholar
• KalteisTBeckmannJSchroderH-JMoxifloxacin superior to vancomycin for treatment of bone infections - a study in ratsActa Orthoped2006a7731519
   PubMed Web of Science ®Google Scholar
• KalteisTBeckmannJSchroderH-JTreatment of implant-associated infections with moxifloxacin: an animal studyInt J Antimicrob Agents2006b27444816621461
   PubMed Web of Science ®Google Scholar
• LabombardiVJShastryLTischlerHMycobacterium thermoresistibile infection following knee-replacement surgeryJ Clin Microbiol2005435393416208028
   PubMed Web of Science ®Google Scholar
• Leal del RosalPFabianGVick-FragasoREfficacy and safety of moxifloxacin (MXF) vs. cephalexin (with or without metronidazole) in the treatment of mild to moderate uncomplicated skin and skin structure infections (uSSSI) [abstract]1999Proceedings of the 39th Interscience Conference on Antimicrobial Agents and ChemotherapySept. 26–29San Diego, CA, USA1076
   Google Scholar
• Leal del RosalPMartinezRFabianGEfficacy and safety of moxifloxacin vs. cephalexin in the treatment of mild to moderate uncomplicated skin and skin structure infections (USSSI)J Antimicrob Chemother199944suppl A148. P493
   Google Scholar
• LemmenSWHafnerHKlikSComparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniaeChemotherapy20034933512714807
   PubMed Web of Science ®Google Scholar
• LettieriJVargasRAgarwalVEffect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteersClin Pharmacokinet200140Suppl 1192511352438
   PubMedGoogle Scholar
• LionCConroyMCCarpentierAMAntimicrobial susceptibilities of Pasturella strains isolated from humansInt J Antimicrob Agents200627290316564680
   PubMed Web of Science ®Google Scholar
• ListerPDPharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic modelClin Infect Dis200132Suppl 1S33811249827
   PubMed Web of Science ®Google Scholar
• LubaschAKellerIBornerKComparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteersAntimicrob Agents Chemother2000442600310991830
   PubMed Web of Science ®Google Scholar
• MacGowanAPBowkerKEHoltHABay 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteriaJ Antimicrob Chemother19974050399372419
   PubMed Web of Science ®Google Scholar
• MalathumKSinghKVMurrayBEIn vitro activity of moxifloxacin, a new 8-methoxyquinolone, against gram-positive bacteriaDiagn Microbiol Infect Dis1999351273310579093
   PubMed Web of Science ®Google Scholar
• MalincarneLGhebregzabherMMorettiMVPenetration of moxifloxacin into bone in patients undergoing total knee arthoplastyJ Antimicrob Chemother200657950416551691
   PubMed Web of Science ®Google Scholar
• ManIMurphyJFergusonJFluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteersJ Antimicrob Chemother199943Suppl B778210382879
   PubMedGoogle Scholar
• MandellGLColemanEUptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophilsAntimicrob Agents Chemother2001451794811353627
   PubMed Web of Science ®Google Scholar
• MilatovicDSchmitzFJBrisseSIn vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolatesAntimicrob Agents Chemother20004411027
   Web of Science ®Google Scholar
• MitscherLBacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agentsChem Rev20051055599215700957
   PubMed Web of Science ®Google Scholar
• MorganrothJDiMarcoJPAnzuetoACAPRIE Study GroupA randomized trial comparing the cardiac rhythm safety of moxifloxacin vs. levofloxacin in elderly patients hospitalized with community-acquired pneumoniaChest2005128339840616304291
   PubMed Web of Science ®Google Scholar
• MullerMStassHBrunnerMPenetration of moxifloxacin into peripheral compartments in humansAntimicrob Agents Chemother1999432345910508004
   PubMed Web of Science ®Google Scholar
• NoelARBowkerKNMacGowanAPPharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic modelAntimicrob Agents Chemother2005494234916189103
   PubMed Web of Science ®Google Scholar
• NoriSNebesioCBrashearRMoxifloxacin-associated drug hypersensitivity syndrome with toxic epidermal necrolysis and fulminant hepatic failure (letter)Arch Dermatol20041401537815611441
   PubMed Web of Science ®Google Scholar
• NovielloSIannielloFLeoneSComparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogensJ Antimicrob Chemother2003528697114519672
   PubMed Web of Science ®Google Scholar
• OdenholtILowdinEGustafssonIPharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic modelAntimicrob Agents Chemother2002462046812019138
   PubMed Web of Science ®Google Scholar
• ParishLCRouthHBMiskinBMoxifloxacin versus cephalexin in the treatment of uncomplicated skin infectionsInt J Clin Prac200054497503
   PubMed Web of Science ®Google Scholar
• Park-WyllieLYJuurlinkDNKoppAOutpatient gatifloxacin therapy and dysglycemia in older adultsN Engl J Med200635413526116510739
   PubMed Web of Science ®Google Scholar
• PatelMVDe SouzaNJGupteSVAntistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection modelsAntimicrob Agents Chemother20044847546115561853
   PubMed Web of Science ®Google Scholar
• PeaFPavanFLugattiEPharmacokinetic and pharmacodynamic aspects of oral moxifloxacin 400 mg/day in elderly patients with acute exacerbation of chronic bronchitisClin Pharmacokinet2006452879516509760
   PubMed Web of Science ®Google Scholar
• Perez-GiraldoCGonzalez-VelascoCSanchez-SilosRMMoxifloxacin and biofilm production by coagulase-negative staphylococciChemotherapy200450101415211086
   PubMed Web of Science ®Google Scholar
• PericMJacobsMRAppelbaumPCAntianaerobic activity of a novel fluoroquinolone, WCK 771, compared with those of nine other agentsAntimicrob Agents Chemother20044831889215273148
   PubMed Web of Science ®Google Scholar
• RaghavanMLindenPKNewer treatment options for skin and soft tissue infectionsDrugs20046416214215257625
   PubMed Web of Science ®Google Scholar
• Rodriguez DiazJCLopezMRuizMIn vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteriaInt J Antimicrob Agents200321585812791475
   PubMed Web of Science ®Google Scholar
• RubinsteinEDiamantsteinLYosephGThe effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coliClin Microbiol Infect200066788111284929
   PubMed Web of Science ®Google Scholar
• RuizJMechanism of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protectionJ Antimicrob Chemother20035111091712697644
   PubMed Web of Science ®Google Scholar
• SableDMurakawaGJQuinolones in dermatologyClin Dermatol200321566312609589
   PubMed Web of Science ®Google Scholar
• SchaumannRAckermannGPlessBIn vitro activities of fourteen antimicrobial agents against obligately anaerobic bacteriaInt J Antimicrob Agents2000162253211091040
   PubMed Web of Science ®Google Scholar
• SchaumannRGoldsteinEJCForbergJActivity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed culturesJ Med Microbiol2005547495316014428
   PubMed Web of Science ®Google Scholar
• SeralCVan BambekeFTulkensPMQuantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophagesAntimicrob Agents Chemother20034722839212821480
   PubMed Web of Science ®Google Scholar
• SillerstromEWahlundENordCEIn vitro activity of ABT-492 against anaerobic bacteriaJ Chemother200416227915330316
   PubMed Web of Science ®Google Scholar
• SnydmanDRJacobusNVMcDermottLAIn vitro activities of newer quinolones against Bacteroides group organismsAntimicrob Agents Chemother2002463276912234859
   PubMed Web of Science ®Google Scholar
• SpecialeAMusumeciRBlandinoGMinimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolatesInt J Antimicrob Agents2002191111811850163
   PubMed Web of Science ®Google Scholar
• StassHDalhoffAKubitzaDPharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjectsAntimicrob Agents Chemother199842206059687407
   PubMed Web of Science ®Google Scholar
• StassHKubitzaDPharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in manJ Antimicrob Chemother199943Suppl B839010382880
   PubMed Web of Science ®Google Scholar
• StassHKubitzaDSchuhlyUPharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administrationClin Pharmacokinet200140Suppl 11911352436
   PubMed Web of Science ®Google Scholar
• StassHKubitzaDHalabiAPharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunctionBr J Clin Pharmacol200253232711874385
   PubMed Web of Science ®Google Scholar
• StassHNagelschmitzJMoellerJGPharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200mg oral itraconazole given once a day in healthy subjectsInt J Clin Pharmacol Ther20044223914756383
   PubMed Web of Science ®Google Scholar
• StefanopoulosPKTarantzopoulouADFacial bite wounds: management updateInt J Oral Maxillofac Surg2005344647216053863
   PubMed Web of Science ®Google Scholar
• StevensDLBisnoALChambersHFPractice guidelines for the diagnosis and management of skin and soft-tissue infectionsClin Infect Dis200541137340616231249
   PubMed Web of Science ®Google Scholar
• StratchounskiLSDekhnichAVKretchikovVAAntimicrobial resistance of nosocomial strains of Staphylococcus aureus in Russia: results of a prospective studyJ Chemother200517546015828444
   PubMed Web of Science ®Google Scholar
• SullivanJTWoodruffMLettieriJPharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinoloneAntimicrob Agents Chemother1999432793710543767
   PubMed Web of Science ®Google Scholar
• SullivanJTLettieriJTLiuPThe influence of age and gender on the pharmacokinetics of moxifloxacinClin Pharmacokinet200140Suppl 1111811352437
   PubMedGoogle Scholar
• TarasiACassoneMMonacoMActivity of moxifloxacin in combination with vancomycin or teicoplanin against Staphylococcus aureus isolated from device-associated infections unresponsive to glycopeptide therapyJ Chemother2003152394312868549
   PubMed Web of Science ®Google Scholar
• TzikourisJPPeetersMJCoxCDEffects of three fluoroquinolones on QT analysis after standard treatment coursesAnn Noninvasive Electrocardiol20061152616472283
   PubMed Web of Science ®Google Scholar
• von EiffCPetersGComparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococciJ Antimicrob Chemother1999435697310350389
   PubMed Web of Science ®Google Scholar
• WenzlerSSchmidt-EisenlohrEDaschnerFComparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infectionsChemotherapy20045040215084805
   PubMed Web of Science ®Google Scholar
• WiseRAndrewsJMMarshallGPharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administrationAntimicrob Agents Chemother19994315081010348784
   PubMed Web of Science ®Google Scholar
• WoodcockJMAndrewsJMBoswellFJIn vitro activity of Bay 12-8039, a new fluoroquinoloneAntimicrob Agents Chemother19974110168980763
   PubMed Web of Science ®Google Scholar
• WrightDHGundersonBWHovdeLBComparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditionsAntimicrob Agents Chemother2002461561311959599
   PubMed Web of Science ®Google Scholar
• YangSCHsuehPRLaiHCHigh prevalence of antimicrobial resistance in rapidly growing mycobacteria in TaiwanAntimicrob Agents Chemother20034719586212760874
   PubMed Web of Science ®Google Scholar